Hosted on MSN17d
Medtronic announces two-year trial outcomes of Evolut TAVR
Those who were eligible, had an aortic valve annulus area of ≤430mm as per the computed tomography measurements, and “suitable” anatomy for transfemoral TAVR with either an Evolut PRO/PRO+/FX or a ...
Stockhouse19d
SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR(TM) system in small annulus patients
2 Eligible patients had an aortic valve annulus area of ≤430 mm as measured by computed tomography, and suitable anatomy for transfemoral TAVR with both an Evolut PRO/PRO+/FX or a SAPIEN 3™/3 Ultra™ ...
PharmiWeb17d
SMART Trial two-year data continues to demonstrate…
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...
Yahoo Finance18d
Medtronic announces two-year trial outcomes of Evolut TAVR
Those who were eligible, had an aortic valve annulus area of ≤430mm as per the computed tomography measurements, and “suitable” anatomy for transfemoral TAVR with either an Evolut PRO/PRO+ ...
Medindia19d
SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR system in small annulus patients
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMa ...